Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers

Autor: Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, Alicia Chenoweth, David E. Thurston, Sophia N. Karagiannis

Publikováno v: Esapa, B, Jiang, J, Cheung, A, Chenoweth, A, Thurston, D & Karagiannis, S N 2023, ' Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers ', Cancers, vol. 15, no. 6, 1845 . https://doi.org/10.3390/cancers15061845

Antibody drug conjugates (ADCs) are powerful anti-cancer therapies comprising an antibody joined to a cytotoxic payload through a chemical linker. ADCs exploit the specificity of antibodies for their target antigens, combined with the potency of cyto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a144c2a1792fe8deeafa3a9445956b80
https://doi.org/10.3390/cancers15061845